10-Q: KalVista Reports First EKTERLY Revenue Amid Global Launches

KalVista Pharmaceuticals reports its first product revenue following the FDA approval and initial commercial launch of EKTERLY for hereditary angioedema, alongside new financing activities.

Summary

• KalVista Pharmaceuticals, Inc. (KalVista) reported its first product revenue of $13.7 million for the three and nine months ended September 30, 2025, following the U.S. FDA approval of EKTERLY (sebetralstat) on July 3, 2025.
• The company initiated commercial sales of EKTERLY in the U.S. and Germany in October 2025.
• Regulatory approvals for EKTERLY were also received from the UK's MHRA (July 2025), European Commission (September 2025), Swissmedic (September 2025), and Australia (October 2025).
• KalVista incurred a net loss of $49.5 million for the three months ended September 30, 2025, an increase from $39.1 million in the prior year period.
• For the nine months ended September 30, 2025, the net loss was $158.9 million, compared to $122.5 million for the same period in 2024.
• Selling, general and administrative (SG&A) expenses significantly increased by 88% to $46.5 million for the three months and 98% to $126.0 million for the nine months ended September 30, 2025, primarily due to commercialization efforts.
• Research and development (R&D) expenses decreased by 36% to $12.0 million for the three months and 41% to $41.2 million for the nine months ended September 30, 2025.
• As of September 30, 2025, KalVista had $243.5 million in cash and cash equivalents and $65.7 million in marketable securities, totaling $309.2 million in liquid assets.
• The company issued $143.8 million in 3.250% Convertible Senior Notes due 2031 in September 2025, with net proceeds of $139.0 million.
• KalVista received an additional $22.0 million payment in July 2025 from DRI Healthcare Acquisitions LP (now DRI UK LP) as part of a royalty agreement, triggered by FDA approval of sebetralstat, increasing the royalty rate on initial sales tranches.
• A License, Supply and Distribution Agreement with Kaken Pharmaceutical Co., Ltd. for exclusive commercialization rights in Japan provided an $11.0 million upfront payment in June 2025, recorded as deferred revenue.

Sentiment

Score: 7

Explanation: The sentiment is positive due to multiple global regulatory approvals for EKTERLY and the successful initiation of product revenue, marking a critical transition to commercialization. Significant financing activities also strengthen the company's liquidity. However, the increased net losses and substantial rise in SG&A expenses reflect the high costs associated with a product launch, tempering the overall positive outlook.

Positives

• EKTERLY (sebetralstat) received multiple key regulatory approvals, including from the U.S. FDA, UK MHRA, European Commission, Swissmedic, and Australia, establishing a broad market presence.
• The company reported its first product revenue of $13.7 million for the three and nine months ended September 30, 2025, marking a significant transition to commercial operations.
• EKTERLY received Orphan Designation in the UK and maintained it in the EU, providing up to 10 years of market exclusivity in these regions.
• The successful Phase 3 KONFIDENT clinical trial results for EKTERLY were published in the New England Journal of Medicine, demonstrating significant symptom relief and a favorable safety profile.
• KalVista secured substantial financing, including $143.8 million from Convertible Senior Notes and an additional $22.0 million from a royalty agreement, bolstering its cash position to $309.2 million.
• A new licensing agreement with Kaken Pharmaceutical Co., Ltd. for Japan provides an $11.0 million upfront payment and potential future milestones and royalties.

Negatives

• The net loss increased to $49.5 million for the three months ended September 30, 2025, from $39.1 million in the prior year, and to $158.9 million for the nine months, from $122.5 million in 2024.
• Operating loss increased to $46.1 million for the three months and $154.7 million for the nine months ended September 30, 2025, reflecting higher expenses.
• Selling, general and administrative (SG&A) expenses rose sharply by 88% to $46.5 million for the three months and 98% to $126.0 million for the nine months, driven by commercialization costs.
• Cash used in operating activities increased to $127.0 million for the nine months ended September 30, 2025, compared to $91.7 million in the prior year, indicating higher cash burn from operations.
• The royalty rate on annual net sales up to $500.0 million increased from 5.00% to 6.00% due to the optional $22.0 million payment from DRI, which will impact future revenue retention.

Risks

• The company anticipates continuing to incur operating losses for the foreseeable future due to global commercialization efforts for EKTERLY and ongoing development activities for expanded patient populations (pediatric patients ages 2-11) and additional product candidates.
• Substantial operating losses may persist even as revenue from EKTERLY increases.
• KalVista is exposed to risks and uncertainties common to pharmaceutical companies with development and commercial operations, including unforeseen expenses, difficulties, complications, delays, and other unknown factors that could adversely affect its business.
• The company may need to seek additional financing through equity offerings, debt financings, corporate partnerships, and product sales to fund future cash needs.

Future Outlook

KalVista anticipates continuing to incur operating losses for the foreseeable future as it focuses on the global commercialization of EKTERLY, expands its treatable patient population to include pediatric patients aged 2-11, and develops additional product candidates. The company expects SG&A expenses to remain at or above current levels to support EKTERLY's commercialization, while R&D expenses are expected to remain approximately at current levels due to ongoing clinical trials (KONFIDENT-S and KONFIDENT-KID) and preclinical research.

Management Comments

• EKTERLY (sebetralstat) is the first and only oral, on-demand therapy for HAE, which has the potential to fundamentally shift the manner in which HAE is managed.
• The efficacy and safety of EKTERLY were established by the results from the phase 3 KONFIDENT clinical trial, published in the New England Journal of Medicine in May 2024, meeting all primary and key secondary endpoints with a favorable safety profile.

Industry Context

The approval of EKTERLY represents a significant advancement in the treatment of Hereditary Angioedema (HAE), as it is the first and only oral, on-demand therapy. This contrasts with previous on-demand options that required intravenous or subcutaneous administration, which carried a significant treatment burden. The introduction of an oral therapy addresses a major unmet need for patients who experience unpredictable attacks, even with long-term prophylaxis, potentially disrupting the existing market for HAE treatments.

Corporate Governance

Legal Proceedings

• The company is not currently aware of any legal proceedings or claims that are believed to have a material adverse effect on its business, financial condition, or operating results.

Related Party Transactions

• In November 2024, KalVista entered into a Purchase and Sale Agreement with DRI Healthcare Acquisitions LP (subsequently amended to DRI UK LP) for royalty financing, receiving an upfront payment of $100.0 million and an additional $22.0 million in July 2025. This agreement involves tiered royalty payments on worldwide net sales of sebetralstat and a sales-based milestone payment.

Stakeholder Impact

• Shareholders: Potential for future dilution from the ATM offering and conversion of senior notes, but also benefit from increased liquidity and the commercialization of EKTERLY.
• Patients: Gain access to a new, orally delivered, on-demand treatment option for HAE, potentially reducing treatment burden compared to injectable therapies.
• Employees: Increased focus on commercialization and global expansion will likely lead to continued growth and opportunities within sales, marketing, and regulatory affairs.
• Creditors (Convertible Note Holders): Benefit from the company's strengthened cash position and potential for future revenue generation from EKTERLY sales, which supports debt repayment capacity.
• DRI Healthcare Trust (Royalty Partner): Benefits from the successful regulatory approvals and commercial launch of EKTERLY, leading to the commencement of royalty payments and potential milestone achievement.

Next Steps

• Continue global commercialization efforts for EKTERLY, with sales initiated in the U.S. and Germany in October 2025.
• Finalize reimbursement plans for EKTERLY in Switzerland, with availability anticipated in the second half of 2026.
• Advance development activities to expand the treatable patient population of EKTERLY to include pediatric patients aged 2-11 through ongoing KONFIDENT-KID trials.
• Continue preclinical research, including the oral Factor XIIa inhibitor program.
• Pursue regulatory reviews for sebetralstat in Japan and Singapore.
• Manage the royalty obligation and potential sales-based milestone payment from DRI Healthcare Trust, with a $57.0 million milestone if annual net sales reach $550.0 million before January 1, 2031.

Key Dates

Recommendation

KalVista Pharmaceuticals has achieved significant milestones with multiple global regulatory approvals for EKTERLY and the initiation of its first product revenue. This transition to a commercial-stage company is a positive development, supported by substantial financing through convertible notes and royalty agreements, which provides a strong cash runway. However, the company is still in the early stages of commercialization, as evidenced by the increased net losses and significantly higher selling, general, and administrative expenses. While the long-term potential for EKTERLY as the first oral on-demand HAE therapy is compelling, the immediate financial performance reflects the heavy investment required for market penetration. Investors should 'hold' to monitor the trajectory of EKTERLY's sales growth, market adoption, and the company's ability to manage its operating expenses and progress its pipeline, as these factors will be crucial for future profitability and stock performance.

Keywords

Biopharmaceuticals, Hereditary Angioedema, HAE, EKTERLY, Sebetralstat, FDA Approval, Commercial Launch, Convertible Notes, Royalty Financing, Rare Diseases, Plasma Kallikrein Inhibitor